These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
870 related articles for article (PubMed ID: 9718378)
1. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group. Cavé H; van der Werff ten Bosch J; Suciu S; Guidal C; Waterkeyn C; Otten J; Bakkus M; Thielemans K; Grandchamp B; Vilmer E N Engl J Med; 1998 Aug; 339(9):591-8. PubMed ID: 9718378 [TBL] [Abstract][Full Text] [Related]
2. PCR detection of clonal IgH and TCR gene rearrangements at the end of induction as a non-remission criterion in children with ALL: comparison with standard morphologic analysis and risk group classification. Scrideli CA; Queiroz RG; Bernardes JE; Valera ET; Tone LG Med Pediatr Oncol; 2003 Jul; 41(1):10-6. PubMed ID: 12764736 [TBL] [Abstract][Full Text] [Related]
3. Detection of T-cell receptor delta gene rearrangement in T-cell malignancies by clonal specific polymerase chain reaction and its application to detect minimal residual disease. Chan DW; Liang R; Kwong YL; Chan V Am J Hematol; 1996 Jul; 52(3):171-7. PubMed ID: 8756082 [TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of detection of monoclonality in remission marrow in acute lymphoblastic leukemia in childhood. Australian and New Zealand Children's Cancer Study Group. Brisco MJ; Condon J; Hughes E; Neoh SH; Nicholson I; Sykes PJ; Tauro G; Ekert H; Waters K; Toogood I Leukemia; 1993 Oct; 7(10):1514-20. PubMed ID: 8412313 [TBL] [Abstract][Full Text] [Related]
5. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase]. zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545 [TBL] [Abstract][Full Text] [Related]
6. Minimal residual disease monitoring in adult T-cell acute lymphoblastic leukemia: a molecular based approach using T-cell receptor G and D gene rearrangements. Gameiro P; Mortuza FY; Hoffbrand AV; Foroni L Haematologica; 2002 Nov; 87(11):1126-34. PubMed ID: 12414341 [TBL] [Abstract][Full Text] [Related]
7. Minimal residual disease (MRD) monitoring using rearrangement of T-cell receptor and immunoglobulin H gene in the treatment of adult acute lymphoblastic leukemia patients. Toubai T; Tanaka J; Ota S; Fukuhara T; Hashino S; Kondo T; Kasai M; Kakinoki Y; Masauzi N; Morioka M; Kawamura T; Iwasaki H; Asaka M; Imamura M Am J Hematol; 2005 Nov; 80(3):181-7. PubMed ID: 16247752 [TBL] [Abstract][Full Text] [Related]
8. Characterization of clonal immunoglobulin heavy chain and I cell receptor gamma gene rearrangements during progression of childhood acute lymphoblastic leukemia. Marshall GM; Kwan E; Haber M; Brisco MJ; Sykes PJ; Morley AA; Toogood I; Waters K; Tauro G; Ekert H Leukemia; 1995 Nov; 9(11):1847-50. PubMed ID: 7475273 [TBL] [Abstract][Full Text] [Related]
9. Molecular detection of minimal residual disease is associated with early relapse in adult acute lymphoblastic leukemia. Specchia G; Liso A; Pannunzio A; Albano F; Mestice A; Pastore D; Liso V Haematologica; 2004 Oct; 89(10):1271-3. PubMed ID: 15477219 [TBL] [Abstract][Full Text] [Related]
11. Detection of minimal residual disease in leukemia using polymerase chain reaction and restriction analysis. Wu N; Lu S; Zhu P; Liu L; Peng Y Chin Med J (Engl); 1997 Jan; 110(1):73-7. PubMed ID: 9594329 [TBL] [Abstract][Full Text] [Related]
12. [Monitoring minimal residual disease in pediatric patients with acute lymphoblastic leukemia]. Zuna J; Hrusák O; Kalinová M; Muzíková K; Zörnerová T; Starý J; Trka J Vnitr Lek; 2000 Aug; 46(8):465-9. PubMed ID: 11048511 [TBL] [Abstract][Full Text] [Related]
13. Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. Roberts WM; Estrov Z; Ouspenskaia MV; Johnston DA; McClain KL; Zipf TF N Engl J Med; 1997 Jan; 336(5):317-23. PubMed ID: 9011783 [TBL] [Abstract][Full Text] [Related]
14. A demographic study of the clinical significance of minimal residual disease in children with acute lymphoblastic leukemia. Levett D; Middleton P; Cole M; Reid MM Med Pediatr Oncol; 2001 Mar; 36(3):365-71. PubMed ID: 11241438 [TBL] [Abstract][Full Text] [Related]
15. Residual disease detection in multiple follow-up samples in children with acute lymphoblastic leukemia. Kitchingman GR Leukemia; 1994 Mar; 8(3):395-401. PubMed ID: 8127144 [TBL] [Abstract][Full Text] [Related]
16. Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia. Steenbergen EJ; Verhagen OJ; van Leeuwen EF; van den Berg H; Behrendt H; Slater RM; von dem Borne AE; van der Schoot CE Leukemia; 1995 Oct; 9(10):1726-34. PubMed ID: 7564517 [TBL] [Abstract][Full Text] [Related]
17. Gamma and delta chain gene rearrangement of T cell receptor in acute lymphoblastic leukemia. Tong JH; Dong S; Chen Y; Qian ZZ; Gu LJ; Zhang YM; Wang ZY; Chen SJ; Chen Z Chin Med J (Engl); 1994 Jan; 107(1):12-8. PubMed ID: 8187567 [TBL] [Abstract][Full Text] [Related]
18. [Preliminary results of the use of MRD test among children with acute lymphoblastic leukaemia]. Raciborska A; Wypych A; Rokicka-Milewska R; Siedlecki JA; Kulik J Przegl Lek; 2004; 61 Suppl 2():62-6. PubMed ID: 15686049 [TBL] [Abstract][Full Text] [Related]